Trial Profile
Study of association between [18F]AV1451 PET and cognition, via direct and/or indirect (mediated by glucose metabolism) pathways, in a cross-sectional sample of amyloid-negative mild cognitive impairment (Aβneg-MCI), amyloid-positive MCI (prodromal AD) and AD dementia patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Oct 2018
Price :
$35
*
At a glance
- Drugs Flortaucipir-F-18 (Primary) ; Flutemetamol-F-18 (Primary)
- Indications Alzheimer's disease; Dementia; Mild cognitive impairment
- Focus Diagnostic use
- 03 Oct 2018 New trial record